Diagnostic and Prognostic Value of Serum Golgi Protein 73 in Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure

IF 3.1 4区医学 Q3 IMMUNOLOGY

Immunity, Inflammation and Disease Pub Date : 2025-02-06 DOI:10.1002/iid3.70120

Zheng-ju Xu, Tao Xu, Qiao-xia Ye, Yong-fei Li, Tian-huang Yang, Xiao-man Zhang, Hui Lin, Hui-guo Liu, Zhi-jie Huang, Jian-kun Shen

{"title":"Diagnostic and Prognostic Value of Serum Golgi Protein 73 in Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure","authors":"Zheng-ju Xu, Tao Xu, Qiao-xia Ye, Yong-fei Li, Tian-huang Yang, Xiao-man Zhang, Hui Lin, Hui-guo Liu, Zhi-jie Huang, Jian-kun Shen","doi":"10.1002/iid3.70120","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>The prognosis and severity of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) cannot be well-identified by serum biomarkers. The present study aims to determine the role of serum Golgi protein 73 (GP73) in predicting the prognosis and severity of liver necrotizing inflammation induced by HBV-ACLF.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 427 chronic HBV-infected patients were included for the present study. Among these patients, 179 patients had chronic hepatitis B (CHB), 96 patients had HBV-related liver cirrhosis (LC), and 152 patients had HBV-ACLF. The baseline and dynamic changes in serum GP73 levels were measured and compared in CHB, LC and HBV-ACLF patients.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The serum GP73 levels were significantly greater in HBV-ACLF patients when compared to CHB and LC patients. Furthermore, serum GP73 demonstrated excellent performance in distinguishing HBV-ACLF from CHB and LC, with an area under the curve of 0.969 and 0.824, respectively. In the logistic regression analysis, a high GP73 level was identified as an independent risk factor associated with death within 3 months, and the optimal cut-off level was 274.59 ng/mL. The serum GP73 levels significantly decreased and remained stable at approximately 6 months for survivors.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Serum GP73 may serve as a valuable biomarker for the diagnosis and prognosis prediction of HBV-ACLF patients.</p>\n </section>\n </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 2","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70120","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity, Inflammation and Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iid3.70120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aims

The prognosis and severity of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) cannot be well-identified by serum biomarkers. The present study aims to determine the role of serum Golgi protein 73 (GP73) in predicting the prognosis and severity of liver necrotizing inflammation induced by HBV-ACLF.

Methods

A total of 427 chronic HBV-infected patients were included for the present study. Among these patients, 179 patients had chronic hepatitis B (CHB), 96 patients had HBV-related liver cirrhosis (LC), and 152 patients had HBV-ACLF. The baseline and dynamic changes in serum GP73 levels were measured and compared in CHB, LC and HBV-ACLF patients.

Results

The serum GP73 levels were significantly greater in HBV-ACLF patients when compared to CHB and LC patients. Furthermore, serum GP73 demonstrated excellent performance in distinguishing HBV-ACLF from CHB and LC, with an area under the curve of 0.969 and 0.824, respectively. In the logistic regression analysis, a high GP73 level was identified as an independent risk factor associated with death within 3 months, and the optimal cut-off level was 274.59 ng/mL. The serum GP73 levels significantly decreased and remained stable at approximately 6 months for survivors.

Conclusion

Serum GP73 may serve as a valuable biomarker for the diagnosis and prognosis prediction of HBV-ACLF patients.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunity, Inflammation and Disease Medicine-Immunology and Allergy

CiteScore

3.60

自引率

0.00%

发文量

146

审稿时长

8 weeks

期刊介绍： Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal is indexed in Medline and the Science Citation Index Expanded (part of Web of Science), among others. It welcomes original work that enhances the understanding of immunology in areas including: • cellular and molecular immunology • clinical immunology • allergy • immunochemistry • immunogenetics • immune signalling • immune development • imaging • mathematical modelling • autoimmunity • transplantation immunology • cancer immunology